Intelligent Bio Solutions Inc. raises $10 million amid stock surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Should l Buy INBS?
Source: Newsfilter
Intelligent Bio Solutions Inc. shares surged by 33.02%, reaching a 20-day high, amid mixed market conditions where the Nasdaq-100 fell by 0.56% and the S&P 500 rose slightly by 0.02%.
The surge is attributed to the company's successful completion of a $10 million private placement with institutional investors, which is expected to enhance liquidity and support future growth initiatives. This financing will be used for working capital and to advance the FDA submission for its Intelligent Fingerprinting Drug Screening System, indicating strong confidence in the product's market potential. Despite the positive financing news, the broader market's mixed performance suggests a sector rotation as investors reassess their positions.
This capital raise not only strengthens Intelligent Bio's financial position but also positions the company for strategic expansion into international markets, particularly in safety-critical industries. The market's reaction reflects a complex interplay of investor sentiment and company-specific developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intelligent Bio Solutions Secures Eighth European Patent
- Patent Grant Progress: Intelligent Bio Solutions has secured its eighth European patent, EP3752831, which relates to contextualizing fingerprint chemical analysis with fingerprint deposition volume, further enhancing its intellectual property protection around fingerprint sweat drug testing technology.
- Innovation Enhancement: The new patent protects a key advancement in analyzing substances in fingerprint sweat by correlating chemical findings with the volume of fingerprint residue during sample collection, thereby improving the robustness and interpretative capacity of the testing process.
- Strengthened Market Position: CEO Harry Simeonidis noted that each patent reinforces the company's market position and protects scientific breakthroughs, making its non-invasive testing approach a compelling alternative to traditional drug screening methods.
- Expanded Application Areas: The company's Intelligent Fingerprinting Drug Testing Solution offers a faster, more dignified alternative for safety-critical sectors, enabling sample collection in seconds and results in under ten minutes, which is expected to positively impact industries such as construction, manufacturing, and transport.
See More
Intelligent Bio Solutions Shares Rise 11% on Manufacturing Partnership Announcement
- Stock Surge: Intelligent Bio Solutions Inc. (INBS) shares rose 11% in pre-market trading following the announcement of a new manufacturing partnership with Syrma Johari MedTech, reflecting strong market confidence in its new product rollout.
- Capacity Expansion: The company reported that its manufacturing capacity has increased to four times its previous level, which is expected to reduce annual production costs by over 40%, thereby enhancing gross margins by approximately 20 percentage points each year, significantly boosting profitability.
- Market Deployment: The newly launched Intelligent Fingerprinting Drug Screening Readers are being deployed across various sectors including construction, transportation, logistics, and manufacturing in the U.K. and Europe, indicating an increasing market penetration in these critical areas.
- Future Outlook: Intelligent Bio Solutions has also doubled its in-house production capacity for test strips and anticipates additional shipments in 2026 as it prepares for entry into the U.S. market, further expanding its market share.
See More
Intelligent Bio Solutions Reports Q2 Earnings
- Earnings Report: Intelligent Bio Solutions reported a Q2 GAAP EPS of -$2.82, indicating ongoing losses despite a significant revenue increase of 45.9% year-over-year to $0.89 million, highlighting challenges in achieving profitability.
- Revenue Growth: The company's revenue rose from $0.61 million in the same quarter last year to $0.89 million, reflecting a 45.9% increase, which suggests improved market demand for its products or services, yet ongoing cost management remains crucial for future profitability.
- Funding Initiative: Intelligent Bio Solutions is launching a $10 million private placement aimed at financing future R&D and market expansion, which could enhance the company's financial flexibility and support long-term growth objectives.
- Market Rating: According to Seeking Alpha's Quant Rating, Intelligent Bio Solutions' market performance is under scrutiny; while revenue growth is notable, persistent losses may undermine investor confidence, necessitating close monitoring of future financial results.
See More
Intelligent Bio Solutions Reports Strong Fiscal 2026 Q2 Results
- Significant Revenue Growth: For the first half of fiscal 2026, Intelligent Bio Solutions reported total revenue exceeding $2 million, reflecting a 36% year-over-year increase, indicating strong demand and sustainable growth potential in the non-invasive drug testing market.
- Doubling of Reader Sales: In Q2, reader sales reached $246,519, up 104% year-over-year, significantly expanding the company's customer base and establishing a solid foundation for future recurring revenue.
- Improved Gross Margins: The gross profit margin for the first half of fiscal 2026 increased to 49%, a 10% improvement from the same period last year, showcasing enhanced operational efficiency and strengthening the company's competitive position.
- Strategic Investments and Partnerships: The company closed a $10 million private placement and formed a strategic alliance with Vlepis Pty Ltd, aiming to enter the rapidly growing consumer health monitoring market and broaden revenue opportunities.
See More
Intelligent Bio Solutions Expects Record Revenue Growth in Q2
- Revenue Growth Expectation: Intelligent Bio Solutions anticipates approximately $2.01 million in revenue for fiscal Q2 2026, reflecting a 36% year-over-year increase, indicating strong growth potential across all product categories.
- Surge in Reader Sales: Reader sales are expected to more than double year-over-year in Q2, which not only expands the installed base but also drives sustained recurring revenue, further solidifying the company's razor-razorblade business model.
- Comprehensive Product Growth: For the first half of fiscal 2026, cartridge sales are projected to increase by 38%, while other sales (accessories, training) are expected to rise by 10%, demonstrating the company's competitive strength and ongoing customer demand.
- Enhanced Market Confidence: The CEO emphasized that the ongoing customer adoption and demand for consumables lay a solid foundation for future revenue growth, which is expected to further enhance market share and bolster confidence in the commercial strategy.
See More
Intelligent Bio Solutions Launches Clinical Study for FDA Clearance
- Clinical Study Launch: Intelligent Bio Solutions has commenced its clinical study program to support the FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, with full data analysis expected by the end of March 2026, marking a pivotal step for the company's entry into the U.S. market.
- Partnership with Cliantha: The company has partnered with Cliantha Research, leveraging their extensive regulatory and clinical trial expertise to ensure the study's effectiveness and compliance, thereby enhancing its competitive position in the market.
- Significant Market Potential: The U.S. drug screening market generates billions annually, and the company's non-invasive fingerprint technology offers superior hygiene and convenience compared to traditional urine and blood testing methods, which is expected to attract a broader customer base.
- Distinct Technological Advantages: With over 500,000 tests sold outside the U.S., the Intelligent Fingerprinting Drug Screening System demonstrates unique advantages across multiple high-value segments, such as workplace testing and law enforcement applications, further driving the company's global market expansion.
See More
Intelligent Bio Solutions Secures Eighth European Patent
- Patent Grant Progress: Intelligent Bio Solutions has secured its eighth European patent, EP3752831, which relates to contextualizing fingerprint chemical analysis with fingerprint deposition volume, further enhancing its intellectual property protection around fingerprint sweat drug testing technology.
- Innovation Enhancement: The new patent protects a key advancement in analyzing substances in fingerprint sweat by correlating chemical findings with the volume of fingerprint residue during sample collection, thereby improving the robustness and interpretative capacity of the testing process.
- Strengthened Market Position: CEO Harry Simeonidis noted that each patent reinforces the company's market position and protects scientific breakthroughs, making its non-invasive testing approach a compelling alternative to traditional drug screening methods.
- Expanded Application Areas: The company's Intelligent Fingerprinting Drug Testing Solution offers a faster, more dignified alternative for safety-critical sectors, enabling sample collection in seconds and results in under ten minutes, which is expected to positively impact industries such as construction, manufacturing, and transport.
See More
Intelligent Bio Solutions Shares Rise 11% on Manufacturing Partnership Announcement
- Stock Surge: Intelligent Bio Solutions Inc. (INBS) shares rose 11% in pre-market trading following the announcement of a new manufacturing partnership with Syrma Johari MedTech, reflecting strong market confidence in its new product rollout.
- Capacity Expansion: The company reported that its manufacturing capacity has increased to four times its previous level, which is expected to reduce annual production costs by over 40%, thereby enhancing gross margins by approximately 20 percentage points each year, significantly boosting profitability.
- Market Deployment: The newly launched Intelligent Fingerprinting Drug Screening Readers are being deployed across various sectors including construction, transportation, logistics, and manufacturing in the U.K. and Europe, indicating an increasing market penetration in these critical areas.
- Future Outlook: Intelligent Bio Solutions has also doubled its in-house production capacity for test strips and anticipates additional shipments in 2026 as it prepares for entry into the U.S. market, further expanding its market share.
See More
Intelligent Bio Solutions Reports Q2 Earnings
- Earnings Report: Intelligent Bio Solutions reported a Q2 GAAP EPS of -$2.82, indicating ongoing losses despite a significant revenue increase of 45.9% year-over-year to $0.89 million, highlighting challenges in achieving profitability.
- Revenue Growth: The company's revenue rose from $0.61 million in the same quarter last year to $0.89 million, reflecting a 45.9% increase, which suggests improved market demand for its products or services, yet ongoing cost management remains crucial for future profitability.
- Funding Initiative: Intelligent Bio Solutions is launching a $10 million private placement aimed at financing future R&D and market expansion, which could enhance the company's financial flexibility and support long-term growth objectives.
- Market Rating: According to Seeking Alpha's Quant Rating, Intelligent Bio Solutions' market performance is under scrutiny; while revenue growth is notable, persistent losses may undermine investor confidence, necessitating close monitoring of future financial results.
See More
Intelligent Bio Solutions Reports Strong Fiscal 2026 Q2 Results
- Significant Revenue Growth: For the first half of fiscal 2026, Intelligent Bio Solutions reported total revenue exceeding $2 million, reflecting a 36% year-over-year increase, indicating strong demand and sustainable growth potential in the non-invasive drug testing market.
- Doubling of Reader Sales: In Q2, reader sales reached $246,519, up 104% year-over-year, significantly expanding the company's customer base and establishing a solid foundation for future recurring revenue.
- Improved Gross Margins: The gross profit margin for the first half of fiscal 2026 increased to 49%, a 10% improvement from the same period last year, showcasing enhanced operational efficiency and strengthening the company's competitive position.
- Strategic Investments and Partnerships: The company closed a $10 million private placement and formed a strategic alliance with Vlepis Pty Ltd, aiming to enter the rapidly growing consumer health monitoring market and broaden revenue opportunities.
See More
Intelligent Bio Solutions Expects Record Revenue Growth in Q2
- Revenue Growth Expectation: Intelligent Bio Solutions anticipates approximately $2.01 million in revenue for fiscal Q2 2026, reflecting a 36% year-over-year increase, indicating strong growth potential across all product categories.
- Surge in Reader Sales: Reader sales are expected to more than double year-over-year in Q2, which not only expands the installed base but also drives sustained recurring revenue, further solidifying the company's razor-razorblade business model.
- Comprehensive Product Growth: For the first half of fiscal 2026, cartridge sales are projected to increase by 38%, while other sales (accessories, training) are expected to rise by 10%, demonstrating the company's competitive strength and ongoing customer demand.
- Enhanced Market Confidence: The CEO emphasized that the ongoing customer adoption and demand for consumables lay a solid foundation for future revenue growth, which is expected to further enhance market share and bolster confidence in the commercial strategy.
See More
Intelligent Bio Solutions Launches Clinical Study for FDA Clearance
- Clinical Study Launch: Intelligent Bio Solutions has commenced its clinical study program to support the FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, with full data analysis expected by the end of March 2026, marking a pivotal step for the company's entry into the U.S. market.
- Partnership with Cliantha: The company has partnered with Cliantha Research, leveraging their extensive regulatory and clinical trial expertise to ensure the study's effectiveness and compliance, thereby enhancing its competitive position in the market.
- Significant Market Potential: The U.S. drug screening market generates billions annually, and the company's non-invasive fingerprint technology offers superior hygiene and convenience compared to traditional urine and blood testing methods, which is expected to attract a broader customer base.
- Distinct Technological Advantages: With over 500,000 tests sold outside the U.S., the Intelligent Fingerprinting Drug Screening System demonstrates unique advantages across multiple high-value segments, such as workplace testing and law enforcement applications, further driving the company's global market expansion.
See More
